NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025
Rhea-AI Summary
NAYA Biosciences (NASDAQ: NAYA) has announced a 1-for-12 reverse stock split effective March 18, 2025, at 12:01 a.m. Eastern Time. The company's stock will continue trading under the symbol 'NAYA' on the Nasdaq Capital Market with a new CUSIP number 44984F609.
Under this reverse split, every 12 shares of common stock will be consolidated into 1 share, with fractional shares rounded up. Post-split, NAYA will have approximately 666,057 shares of common stock outstanding, and its authorized shares will be adjusted to 4,166,666.
The primary objective of this reverse split is to meet Nasdaq's minimum bid price requirement of $1.00 per share for continued listing, though compliance is not guaranteed. NAYA Biosciences focuses on breakthrough treatments in oncology, autoimmune diseases, women's health, and provides IVF and IVC fertility treatments.
Positive
- Potential to maintain Nasdaq listing compliance through bid price increase
Negative
- Risk of failing to meet Nasdaq minimum bid requirement despite reverse split
- Significant share consolidation (12:1) indicates serious price decline
- No guarantee of maintaining Nasdaq listing
News Market Reaction
On the day this news was published, NAYA declined 33.76%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on March 18, 2025, the Company’s common stock will trade on a post-split basis under the same trading symbol, “NAYA”.
As a result of the reverse stock split, the CUSIP number for the Company’s common stock will be 44984F609. As a result of the reverse stock split, every 12 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share. Immediately after the reverse stock split becomes effective, the company will have approximately 666,057 shares of common stock issued and outstanding. In addition, a proportionate adjustment will be made to the company’s authorized shares of common stock such that the Company shall have 4,166,666 shares of authorized common stock after the effective time of the reverse stock split.
The reverse stock split is primarily intended to bring the Company into compliance with Nasdaq’s
About NAYA Biosciences
NAYA Biosciences (NASDAQ: NAYA) is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health. Our proven hub & spoke model harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets and allowing for optimized return on investment by combining scalable, profitable commercial revenues with the upside of innovative clinical-stage therapeutics.
NAYA’s expanding portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a unique mode of action targeting non-responders to the current immunotherapy standard of care (approximately
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
NAYA Bioscience
Steve Shum, CEO
978-878-9505
sshum@invobio.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ
What is the ratio of NAYA's reverse stock split announced for March 2025?
When will NAYA's reverse stock split take effect?
How many shares will NAYA have outstanding after the March 2025 reverse split?
Why is NAYA implementing a reverse stock split in March 2025?
